1. 基于天然产物的创新药物研究；
2. 小分子抗肿瘤免疫药物的开发；
3. 药物绿色合成工艺和晶型研究。

1. 国家自然科学基金面上项目，81872746、靶向CDK9的小分子抑制剂的结构优化及其在急性髓细胞白血病中的应用、2019.1-2022.12、57万元、在研、主持。
2. 国家自然科学基金面上项目，21372260、新型雄激素受体拮抗剂的设计与合成及活性研究、2014.1-2017.12、80万元、结题、主持。
3. 国家自然科学基金面上项目，21072232、具有肿瘤多靶点作用特征的汉黄芩素衍生物的研究、2011.1-2013.12、36万元、结题、主持。
4. 江苏省自然科学基金面上项目，靶向色氨酸-犬尿氨酸通路中关键双加氧酶的全新骨架抑制剂的研究，BK20171393，主持，10万元，2017.07-2020.07。
5. “重大新药创制”科技重大专项，国家抗肿瘤1类新药GL-V9原料与制剂临床前研究，110 万。
① 研发具有自主知识产权的国家Ⅰ类抗晚期肝癌原创新药CPU-118片，顺利通过了国家药品监督管理局药品审评中心（CDE）审批，获得临床试验通知书，目前处于临床I期研究。
② 化药1类创新药物新型JAK抑制剂的专利成果转化，总金额为5000万元。
③ 完成多个小分子抗新冠病毒药物的绿色合成工艺，转化总额达500万元。
6. 新型抗类风湿新药KDN30000项目的药物分子设计及合成研究，110万，校企联合项目。
7. DKLS原料及其滴眼剂的研制开发(校合2018-药116)，1000万，校企联合项目。

1.Yucheng Tian, Kang Liu, Ruoyi Liu, Zhixia Qiu, Yifan Xu, Wei Wei, Xi Xu, Jubo Wang, Hong Ding, Zhiyu Li*; Jinlei Bian*, Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. Journal of Medicinal Chemistry, 2022, 65: 8914-8932. (IF: 8.039)
2. Xi Xu#; Jubo Wang#; Min Wang; Xinyu Yuan; Lei Li; Chao Zhang; Huidan Huang*; Tian Jing; Chenchen Wang; Chao Tong; Liwen Zhou; Ying Meng; Pengfei Xu; Junping Kou; Zhixia Qiu; Zhiyu Li*; Jinlei Bian*, Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site, Journal of Medicinal Chemistry, 2021, 64: 4588-4611. (IF: 8.039)
3.Zhen Qin#; Bin Dong#; Renbing Wang; Dechun Huang; Jubo Wang*; Xi Feng; Jinlei Bian*; Zhiyu Li*, Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning, Acta Pharmaceutica Sinica B, 2021, 11: 3678-3682. (IF: 14.903)
4.Kai Yuan, Minghui Ji, Shengnan Xie, Zhixia Qiu, Weijiao Chen, Wenjian Min, Fei Xia, Mingming Zheng, Xiao Wang, Jiaxing Li, Yi Hou, Wenbin Kuang, Liping Wang, Wanjian Gu*, Zhiyu Li* and Peng Yang*. Journal of Medicinal Chemistry, 2022, 65: 857-875. (IF: 8.039)
5.Zhen Qin; Lian Qin; Xi Feng; Zhiyu Li*; Jinlei Bian*, Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions. Journal of Medicinal Chemistry, 2021, 64: 13191-13211. (IF: 8.039)
6.Yucheng Tian#; Jubo Wang#; Xinying Cheng; Kang Liu; Tizhi Wu; Xiaqiu Qiu; Zijian Kuang; Zhiyu Li*; Jinlei Bian*, Microwave-assisted unprotected Sonogashira reaction in water for the synthesis of polysubstituted aromatic acetylene compounds, Green Chemistry, 2020, 22:1338-1344. (IF: 11.034)
7.Xi Feng; Dongdong Liao; Dongyu Liu; An Ping; Zhiyu Li*; Jinlei Bian*, Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective, Journal of Medicinal Chemistry, 2020, 63: 15115-15139. (IF: 8.039)
8.Xi Xu; Zijian Kuang; Jie Han; Ying Meng; Lei Li; Hongyu Luan; Pengfei Xu; Jubo Wang; Cheng Luo; Hong Ding; Zhiyu Li*; Jinlei Bian*, Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors, Journal of Medicinal Chemistry, 2019, 62: 9642-9657. (IF: 8.039)
9.Tizhi Wu, Zhen Qin, Yucheng Tian, Jubo Wang, Chenxi Xu, Zhiyu Li* and Jinlei Bian*. Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. Journal of Medicinal Chemistry, 2019, 62: 9642−9657. (IF: 8.039)
10.Xi Xu, Ying Meng, Lei Li, Pengfei Xu, Jubo Wang, Zhiyu Li* and Jinlei Bian*.Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. Journal of Medicinal Chemistry, 2019, 62: 1096−1115. (IF: 8.039)
11.Qianming Du#; Xi Feng#; Yinuo Wang; Xi Xu; Yan Zhang; Xinliang Qu; Zhiyu Li*; Jinlei Bian*, Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer, European Journal of Medicinal Chemistry, 2019, 182: 111629. (IF: 7.088).

卞金磊副教授、邱志霞副教授、吴红茜副教授、钟毅副教授、毕小玲副教授等